Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $50 price target on Arrowhead Pharmaceuticals after the company presented first in man data for ARO-APOC3 and ARO-ANG3 at the Global Summit on Cardiology and Heart Diseases in Dubai. In a research note to investors, Tenthoff syas that in healthy volunteers, single doses of ARO-APOC3 resulted in 66% lowering of triglycerides and 63% for ARO-ANG3 through week 12. He looks for Arrowhead to initiate the Phase II/III SEQUOIA trial of ARO-AAT and file CTAs on two additional TRiM candidates ARO-HIF2 and ARO-HSD this year.

Arrowhead Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial, NCT06209177 or of ARO-CFB, the company's investigational RNA interference RNAi therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease. James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: "In preclinical studies, ARO-CFB achieved deep and durable reductions in liver production of complement factor B, which is involved in alternative complement pathway activation and associated with pathogenesis of diseases involving complement activation. ARO-CFB is our second clinical program designed to address diseases associated with activation of the complement pathway, the first being ARO-C3, our Phase 1 program targeting complement component 3. We look forward to further progressing both programs to investigate whether these candidates can address the substantial unmet medical need that remains in the treatment of multiple complement mediated diseases." ARO-CFB is designed to reduce hepatic expression of complement factor B CFB , which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target. ARO-CFB is being developed as a potential treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy IgAN , which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease. Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.